e-learning
resources
Vienna 2003
Sunday 28.09.2003
Advances in our understanding of corticosteroids in the treatment of asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β
2
-agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells
H. Boushey, P. Woodruff, G. Dolganov, P. Dorinsky, J. Fahy (San Francisco, Raleigh, United States Of America)
Source:
Annual Congress 2003 - Advances in our understanding of corticosteroids in the treatment of asthma
Session:
Advances in our understanding of corticosteroids in the treatment of asthma
Session type:
Poster Discussion
Number:
347
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Boushey, P. Woodruff, G. Dolganov, P. Dorinsky, J. Fahy (San Francisco, Raleigh, United States Of America). Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β
2
-agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells. Eur Respir J 2003; 22: Suppl. 45, 347
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation
Source: Eur Respir J 2001; 18: Suppl. 33, 261s
Year: 2001
Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness
Source: Eur Respir J 2006; 27: 1144-1151
Year: 2006
Inhaled corticosteroids and growth of airway function in asthmatic children
Source: Eur Respir J 2004; 23: 861-868
Year: 2004
Effect of add-on montelukast to inhaled corticosteroids on excessive airway narrowing in adult asthmatics
Source: Annual Congress 2009 - Aspects of clinical asthma
Year: 2009
Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma
Source: Eur Respir J 2002; 20: 1080-1087
Year: 2002
The effect of inhaled corticosteroids on airway mast cells in type 2 low asthma
Source: Virtual Congress 2020 – Asthma pharmacology: clinical trials and mechanistic insights
Year: 2020
Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma
Source: Eur Respir J 2001; 17: 374-379
Year: 2001
Changes in objective markers following inhaled corticosteroids (ICS) in asthmatics with airway hyperresponsiveness (AHR) to mannitol
Source: International Congress 2019 – Airway physiology
Year: 2019
Effects of intervention with high-dose inhaled corticosteroids on airway remodelling in diagnosed genetic variants of
IL13
with asthma
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010
Influence of formoterol alone and its fixed combination with budesonide on airway responsiveness and airway inflammation induced by repeated low dose allergen challenge
Source: Eur Respir J 2007; 30: Suppl. 51, 749s
Year: 2007
Inhaled corticosteroid (ICS) induced metabolome changes in asthmatics.
Source: Virtual Congress 2020 – Cutting edge science: novel molecules and mechanisms of airway diseases
Year: 2020
Combination of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA)
versus
similar ICS dose in children and adults with persistent asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005
Efficacy of systemic corticosteroids in refractory asthmatics showing no bronchial reversibility with high-dose inhaled corticosteroids or β
2
agonist inhalation
Source: Annual Congress 2010 - Clinical aspects and treatment of asthma and allergic respiratory diseases
Year: 2010
Dose-related effect of inhaled fluticasone on allergen-induced airway changes in rats
Source: Eur Respir J 2002; 20: 873-879
Year: 2002
E-cadherin (
CDH-1
) polymorphisms associate with airway remodeling, inflammation and FEV
1
decline in asthma patients using inhaled corticosteroids (ICS)
Source: Annual Congress 2010 - The impact of genes and environment on obstructive airway diseases
Year: 2010
Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma
Source: Eur Respir J 2009; 33: 1277-1286
Year: 2009
Salmeterol/fluticasone combination (SFC) is associated with improved asthma control compared with concurrent long-acting β
2
agonists (LABA) and inhaled corticosteroids (ICS) or ICS alone
Source: Eur Respir J 2003; 22: Suppl. 45, 235s
Year: 2003
First choice in persistent asthma: inhaled corticosteroids (ICS) or ICS + long-acting beta2-agonist (LABA) combination in steroid-naïve patients?
Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids
Year: 2004
Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment
Source: Eur Respir J 2006; 27: 964-971
Year: 2006
Inhaled budesonide/formoterol combination therapy significantly attenuates allergen-induced increases in airway myfibroblasts
Source: Eur Respir J 2007; 30: Suppl. 51, 137s
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept